Intuniv XR 4 mg (Guanfacine (Guanfacine Hydrochloride) TABLET (EXTENDED-RELEASE)) 4 MG

Intuniv XR 4 mg is an extended-release tablet containing guanfacine hydrochloride, used for managing certain conditions. This medication is designed for oral use and offers a prolonged effect.

Strength

4 MG

Manufacturer / TM Owner

TAKEDA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Intuniv XR 4 mg is primarily used for the treatment of attention deficit hyperactivity disorder (ADHD). It works by affecting certain chemicals in the brain to improve focus and impulse control. This medication is often prescribed as part of a comprehensive treatment plan that may include other therapies.

Side Effects

Common effects of Intuniv XR 4 mg may include drowsiness, dry mouth, and dizziness. Some users might experience fatigue or a decrease in blood pressure. These effects can vary from person to person and may subside as the body adjusts to the medication.

Precautions & Warnings

Intuniv XR 4 mg should be handled with care, especially by individuals with a history of low blood pressure or heart conditions. It is important to follow the prescribed dosage and consult a healthcare provider before starting or stopping the medication. Keep the tablets out of reach of children and store them as directed.

Avoid Interactions

Intuniv XR 4 mg may interact with other medications, including those that lower blood pressure or cause drowsiness. Alcohol and certain supplements can also affect its efficacy. Always inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.

Frequently Asked Questions

Intuniv XR 4 mg is used to manage symptoms of attention deficit hyperactivity disorder (ADHD) by improving focus and impulse control.

Intuniv XR 4 mg is taken orally, typically once daily. Follow the instructions provided by your healthcare provider for the best results.

Common side effects may include drowsiness, dry mouth, dizziness, and fatigue. These effects can vary and may lessen over time.

It is generally advised to avoid alcohol while taking Intuniv XR 4 mg, as it may increase the risk of side effects like drowsiness.

Intuniv XR 4 mg may not be suitable for everyone, especially those with certain heart conditions or low blood pressure. Consult a healthcare provider before use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.